ĐẶC ĐIỂM ĐIỀU TRỊ BỆNH NHÂN UNG THƯ TUYẾN GIÁP THỂ BIỆT HÓA DI CĂN PHỔI VÀ DI CĂN XƯƠNG BẰNG I-131

Abstract

Objective: To survey the characteristics and treatment results of patients with differentiated thyroid cancer with lung and bone metastases using the I-131 method. methods: The study describes a series of prospective cases examining 41 cases of patients with confirmed diagnosis of differentiated thyroid carcinoma by histopathology after surgery with bone metastases or metastases. Lungs at the Department of Nuclear Medicine, Ho Chi Minh City Oncology Hospital from January 2013 to December 2022. Results: Average age 52.29 ± 14.55 years. Lung metastasis accounts for 53.7% and bone metastasis accounts for 46.3%. The treatment-resistant subgroup I-131 according to ETA is mainly group 4, accounting for 73.2%. The median dose of I-131 at the time of treatment resistance was 650 (600 - 750). Median final I-131 dose was 1050 (800 - 1350). Serum Tg and Anti Tg test values before treatment and after treatment were statistically significant. However, there was no difference in blood cell changes. Most patients had structural incomplete response, accounting for 95.1%. The main lesion is bone destruction in 17.1% of patients with bone metastases. Conclusion: Most patients had structural incomplete response, accounting for 95.1%. Reversible bone marrow suppression (7.3%) and death (12.2%) were recorded.